Supplemental Material: Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa

Supplemental Material for the manuscript titled "Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension", published in the Journal of the American Academy of Dermatology.

Contents:
Supplementary Methods 1. Prespecified safety topics of interest
Supplementary Figure 1: BE HEARD I and II and BE HEARD Extension study design
Supplementary Figure 2: Safety pooled data
Supplementary Figure 3: Missing data handling
Supplementary Figure 4: HiSCR50/75/90/100 over time in BKZ Total patients (mNRI [AE-LoE])
Supplementary Figure 5: Efficacy- and lesion-based outcomes over time in BKZ Total patients (MI [AE-LoE] and mNRI [AE-LoE])
Supplementary Table 1. HiSCR50/75/90/100 to Week 96 in patients receiving BKZ Q2W/Q4W/Q4W (OC)

发表于《美国皮肤病学会杂志》的题为《比美吉珠单抗（Bimekizumab）在中重度化脓性汗腺炎患者中长达2年治疗时展现出良好安全性特征与优异疗效水平：两项3期随机对照试验及其开放-label扩展试验的汇总分析》的手稿补充材料。

内容：
补充方法1：预设关注的安全性研究主题
补充图1：BE HEARD I、BE HEARD II及BE HEARD扩展试验研究设计
补充图2：安全性汇总数据
补充图3：缺失数据处理方案
补充图4：比美吉珠单抗总人群中HiSCR50/75/90/100指标随时间变化情况（mNRI [AE-LoE]）
补充图5：比美吉珠单抗总人群中基于疗效与皮损的结局指标随时间变化情况（MI [AE-LoE]及mNRI [AE-LoE]）
补充表1：接受BKZ Q2W/Q4W/Q4W（OC）治疗的患者截至第96周的HiSCR50/75/90/100情况